| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/23/2012 | CA2808372A1 Methods of generating oligodendrocytes and cell populations comprising same |
| 02/23/2012 | CA2808210A1 Composition comprising tetracyclic compound |
| 02/23/2012 | CA2807778A1 Anti-cancer adenoviruses |
| 02/23/2012 | CA2807776A1 1,5-diphenyl-penta-1,4-dien-3-one compounds |
| 02/23/2012 | CA2807364A1 Oxadiazole inhibitors of leukotriene production |
| 02/23/2012 | CA2807307A1 Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina) |
| 02/23/2012 | CA2807222A1 Combination anti - cancer therapy |
| 02/23/2012 | CA2807218A1 Novel combination therapy for the treatment of cancer |
| 02/23/2012 | CA2806637A1 Antibodies for epidermal growth factor receptor 3 (her3) |
| 02/23/2012 | CA2805176A1 Humanized anti-interleukin 3 receptor alpha chain antibodies |
| 02/22/2012 | EP2420515A1 Diagnosis and treatment of cancer using anti-tmprss11e antibody |
| 02/22/2012 | EP2420512A2 Anti-VEGF antibodies |
| 02/22/2012 | EP2420500A1 Pyridine thio derivative, and pharmaceutical composition which contains same and has anti-helicobacter pylori action |
| 02/22/2012 | EP2420498A1 5-substituted quinazolinone derivatives as anti-cancer agents |
| 02/22/2012 | EP2420497A1 5-substituted quinazolinone derivatives as anti-cancer agents |
| 02/22/2012 | EP2420490A1 (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: Methods of using and compositions thereof |
| 02/22/2012 | EP2420289A1 Composition of caffeic acid phenethyl ester (CAPE) and one of catechin, kaempherol and myricetin for potentiating antitumour effect and for treating tumours |
| 02/22/2012 | EP2420255A2 Polypeptide inhibitors of urokinase type plasminogen activator |
| 02/22/2012 | EP2420252A1 EPHB3-specific antibody and uses thereof |
| 02/22/2012 | EP2420249A1 Vaccine immunotherapy for immune suppressed patients |
| 02/22/2012 | EP2420242A1 Oncolytic measles virus |
| 02/22/2012 | EP2420239A2 Antiangiogenic agents |
| 02/22/2012 | EP2420238A2 Anti-angiogenic agents |
| 02/22/2012 | EP2420236A2 Anti-angiogenic agents |
| 02/22/2012 | EP2420230A2 Antiangiogenic agents |
| 02/22/2012 | EP2420229A1 S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer |
| 02/22/2012 | EP2420228A1 Composition comprising retinol, a precursor or a reaction product of it and a plant extract from at least one chamomilla plant for the treatment of cancer |
| 02/22/2012 | EP2420227A1 Targeted sustained-release microsphere of vascular occlusive agent containing sodium alginate and sorafenib, production method and use thereof |
| 02/22/2012 | EP2419737A2 Histone modification patterns for clinical diagnosis and prognosis of cancer |
| 02/22/2012 | EP2419451A1 Antibodies against prostate specific membrane antigen |
| 02/22/2012 | EP2419440A1 Peptide ligands for clusterin and uses thereof |
| 02/22/2012 | EP2419432A1 Pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
| 02/22/2012 | EP2419429A1 Imidazopyrazines for use as kinase inhibitors |
| 02/22/2012 | EP2419428A1 Imidazo [1,2-a]pyridine derivatives as fgfr kinase inhibitors for use in therapy |
| 02/22/2012 | EP2419427A1 Bicyclic heterocyclyl derivatives as fgfr kinase inhibitors for therapeutic use |
| 02/22/2012 | EP2419425A1 Imidazole substituted pyrimidines useful in the treatment of glycogen synthase kinase 3 related disorders such as alzheimer's disease |
| 02/22/2012 | EP2419424A2 Substituted 4-amino-5-benzoyl-2-(phenylamino)thiophene-3-carbonitriles and substituted 4-amino-5-benzoyl-2-(phenylamino)thiophene-3-carboxamides as tubulin polymerization inhibitors |
| 02/22/2012 | EP2419423A1 Fluoro substituted pyrimidine compounds as jak3 inhibitors |
| 02/22/2012 | EP2419422A1 Imidazolidine-2,4-dione derivatives and use thereof as a medicament |
| 02/22/2012 | EP2419414A1 Protein phosphatase 2a-activating agents |
| 02/22/2012 | EP2419411A1 Quinoxaline derivatives and their use for treating benign and malignant tumour disorders |
| 02/22/2012 | EP2419410A1 Imidazolidine-2,4-dione derivatives, and use thereof as a cancer drug |
| 02/22/2012 | EP2419177A1 Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors |
| 02/22/2012 | EP2419143A1 Hpv particles and uses thereof |
| 02/22/2012 | EP2419140A2 Diazeniumdiolated phosphorylcholine polymers for nitric oxide release |
| 02/22/2012 | EP2419136A2 Compositions and methods for treating cancer |
| 02/22/2012 | EP2419126A1 Combination immunotherapy compositions against cancer and methods |
| 02/22/2012 | EP2419121A2 Peptides targeting tnf family receptors and antagonizing tnf action, compositions, methods and uses thereof |
| 02/22/2012 | EP2419111A1 Sensitizing agents for cancer therapy, methods of use and methods for the identification thereof |
| 02/22/2012 | EP2419106A1 Benzodiazepine derivative for the treatment of hematopoietic neoplasm and leukemia |
| 02/22/2012 | EP2419101A2 Method of treating disorders associated with protein kinase ck2 activity |
| 02/22/2012 | EP2419100A2 Method of decreasing pro-adam10 secretase and/or beta secretase levels |
| 02/22/2012 | EP2419095A2 Pharmaceutically active compositions comprising oxidative stress modulators (osm), new chemical entities, compositions and uses |
| 02/22/2012 | EP2418956A1 Method of treating hepatocellular carcinoma |
| 02/22/2012 | EP2418955A1 High bioavailability oral picoplatin anti-cancer therapy |
| 02/22/2012 | EP2418948A1 Antiadhesion agents |
| 02/22/2012 | EP2418943A1 Curcumin analogs as dual jak2/stat3 inhibitors and methods of making and using the same |
| 02/22/2012 | EP2361988A9 Molecular marker for cancer stem cell |
| 02/22/2012 | EP2310382B1 Amidophenoxyindazoles useful as inhibitors of c-met |
| 02/22/2012 | EP2093228B1 Pyrroline-2-one derivatives against cell releasing tumor necrosis factor, preparation methods and uses thereof |
| 02/22/2012 | EP1906977B1 Stabilized chlorite solutions in combination with fluoropyrimidines for cancer treatment. |
| 02/22/2012 | EP1799268B1 Magnetic particles for therapy and diagnosis |
| 02/22/2012 | EP1708752B1 Polymer-bound antibody cancer therapeutic agent |
| 02/22/2012 | EP1691836B1 Anti-pecam therapy for metastasis suppression |
| 02/22/2012 | EP1668013B1 Pyrazolopyrrole derivatives as protein kinase inhibitors |
| 02/22/2012 | EP1648494B1 Anti-angiogenetic agent and its use in cancer treatment |
| 02/22/2012 | EP1590328B1 (2-carboxamido) (3-amino) thiophene compounds |
| 02/22/2012 | EP1534680B1 Prenylation inhibitors and methods of their synthesis and use |
| 02/22/2012 | EP1534289B2 Adenosine a2a receptor antagonists for treating restless legs syndrome or nocturnal myoclonus |
| 02/22/2012 | EP1531850B1 Use of IL-21 and monoclonal antibody for treating solid cancers |
| 02/22/2012 | EP1507778B1 Anti-tumour polycyclic carboxamides |
| 02/22/2012 | EP1095183B1 Methods for the diagnosis and treatment of lung cancer |
| 02/22/2012 | EP0986384B1 Inhibitors of protein isoprenyl transferases |
| 02/22/2012 | CN1943780B 胰激肽原酶在制备放射治疗肿瘤的药物中的应用 Pancreatic kallikrein in the manufacture of a medicament for radiation therapy of cancer |
| 02/22/2012 | CN102361985A Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene |
| 02/22/2012 | CN102361883A Bispecific anti-erbb-1/anti-c-met antibodies |
| 02/22/2012 | CN102361872A Fused pyrimidines as AKT inhibitors |
| 02/22/2012 | CN102361870A Propane- i-sulfonic acid {3- [5- (4 -chloro-phenyl) -1h-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof |
| 02/22/2012 | CN102361859A Heteroaryl compounds useful as Raf kinase inhibitors |
| 02/22/2012 | CN102361853A Toluidine sulfonamides and their use |
| 02/22/2012 | CN102361646A Compounds and methods for modulating immune response |
| 02/22/2012 | CN102361636A Amino acid-conjugated cyanoacrylate polymer particles |
| 02/22/2012 | CN102358901A Antitumor application of has-miR-520e |
| 02/22/2012 | CN102358752A GLP-1 and exendin related invention |
| 02/22/2012 | CN102358750A Helix 12 directed pharmaceutical products |
| 02/22/2012 | CN102358742A Thiazole compound with antitumor activity |
| 02/22/2012 | CN102358730A Micromolecular methyl ethyl ketone (MEK) protein kinase inhibitor |
| 02/22/2012 | CN102357250A Magnetic resonance imaging (MRI)-oriented high intensity focused ultrasound (HIFU) synergist and preparation method thereof |
| 02/22/2012 | CN102357247A Therapeutic methods and delivery systems utilizing sex steroid precursors |
| 02/22/2012 | CN102357246A EGFR and HER2 combined polypeptide epitope vaccine |
| 02/22/2012 | CN102357229A Traditional Chinese medicine for treating thyroma |
| 02/22/2012 | CN102357211A Traditional Chinese medicine composition for curing cancers |
| 02/22/2012 | CN102357206A Mountain toad detumescence mass-dissipating detoxication pellets and preparation method |
| 02/22/2012 | CN102357202A Traditional Chinese medicine cancer toxin prescription for treating liver cancer and application thereof in pharmacy |
| 02/22/2012 | CN102357194A Traditional Chinese medicine composition for preventing and treating lung injury due to radioactive radon and daughters thereof |
| 02/22/2012 | CN102357189A Traditional Chinese medicine for radiotherapy regulation and nourishment |
| 02/22/2012 | CN102357180A Traditional Chinese medicine composite for curing cancer and preparation method and application thereof |
| 02/22/2012 | CN102357159A Bezoar anticancer pill |
| 02/22/2012 | CN102357123A Application of herba dicranostigmae alcohol extract in preparing medicines for resisting melanoma transfer |
| 02/22/2012 | CN102357117A Pogostemon cablin volatile oil, preparation method thereof and application thereof to prepare anti-tumor medicines |